Aspreva's plan of arrangement with Galenica completed

07-Jan-2008

Aspreva Pharmaceuticals Corporation announced the completion of the plan of arrangement with Galenica Group, pursuant to which Galenica, through a wholly-owned Canadian subsidiary, acquired all outstanding shares of Aspreva for US$26.00 per share in cash.

With the completion of the plan of arrangement, Aspreva will delist its shares from the NASDAQ on January 3, 2008 and the Toronto Stock Exchange on January 7, 2008.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance